Vericiguat (Verquvo)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses vericiguat (Verquvo), 2.5 mg, 5 mg, 10 mg, orally administered, film-coated tablets. Indication: For the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or IV diuretic therapy. Verquvo should be used in combination with standard-of-care therapy for heart failure.